Target intelligence / Profile preview

Gut microbiota-brain axis

Molecular classification
Other (communication network/system)
01

Overview

The gut microbiota-brain axis describes a complex, bidirectional information network connecting the gut microbiota and the brain through neural (including vagus nerve), endocrine, immune, and metabolic pathways. This axis influences brain development, cognition, emotional regulation, immune function, and barrier integrity (both gut and blood-brain barriers); disruptions in the axis have been linked to neurodegenerative diseases, psychiatric disorders, and functional gut disorders. As a concept, the gut microbiota-brain axis is being targeted therapeutically via strategies that modify the microbial community (e.g., probiotics, prebiotics, FMT) or its metabolites, rather than through targeting a single molecule or receptor. The axis is neither a discrete molecular entity nor a canonical drug target, but rather a physiological and microbiological network implicated in health and disease.

Other names
Gut-brain axisMicrobiota-gut-brain axisMicrobiome-gut-brain axis
02

Mechanism of action

Modulation of gut microbial composition; Regulation of neuroactive metabolite production (e.g., SCFAs, neurotransmitters); Alteration of immune system signaling; Impact on neuroendocrine signaling (HPA axis)

03

Biological functions

Signal transductionNeuroendocrine regulationImmune responseRegulation of neurotransmitter synthesis and metabolismModulation of brain structure and functionMaintenance of barrier integrity (intestinal and blood-brain barrier)
04

Disease associations

Neurodegenerative disease (e.g. Alzheimer’s, Parkinson’s, ALS)Neuropsychiatric disorder (e.g. depression, anxiety, schizophrenia, bipolar disorder)Functional gastrointestinal disorders (e.g. irritable bowel syndrome)Substance use disorderOther disorders involving immune or endocrine dysregulation
05

Safety considerations

Unintended immune modulationDysbiosis or negative shifts in microbiotaNeuropsychiatric effects (unpredictable cognitive/emotional outcomes from intervention)Transmission of pathogens in FMT
06

Interacting drugs

Probiotics

3 more in the full profile.

07

Biomarkers

Gut microbial composition/profile (metagenomic markers)Levels of neuroactive metabolites (e.g., short-chain fatty acids, serotonin)Inflammatory markers in blood or gutBarrier integrity markers (intestinal/BBB permeability)

Beyond the preview

Go deeper on Gut microbiota-brain axis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota-brain axis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call